Condition
SARS-CoV
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05938075Phase 1CompletedPrimary
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
NCT05870839Phase 1CompletedPrimary
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
NCT04583319CompletedPrimary
Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection
NCT04503525CompletedPrimary
Nutritional Assessment of Hospitalized Patients With COVID-19
Showing all 4 trials